文献速递炎症性肠病

抗TNF治疗引入未降低IBD住院与手术率:基于人群的间断时间序列研究

Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
PubMed 文献 · Gut · 2019-06-12

该研究利用加拿大安大略省1995-2012年成人CD和UC患者卫生行政数据,采用间断时间序列分析评估英夫利昔单抗上市对IBD相关住院、肠切除和公共支付药物成本的影响。结果显示,英夫利昔单抗上市未显著降低CD相关住院(OR 1.06)或肠切除(OR 1.10)率,也未显著降低UC相关住院(OR 1.22)或结肠切除(OR 0.933)率;但英夫利昔单抗使用者中UC患者住院率显著下降(OR 0.515)。CD患者公共支付药物成本较预期趋势上升约三倍(OR 2.98)。

要点

  • 英夫利昔单抗上市未显著降低CD相关住院(OR 1.06)或肠切除(OR 1.10)率。
  • 英夫利昔单抗上市未显著降低UC相关住院(OR 1.22)或结肠切除(OR 0.933)率。
  • CD患者公共支付药物成本较预期趋势上升约三倍(OR 2.98)。

核心结论

  • 英夫利昔单抗上市未产生预期的IBD相关住院或肠切除人群率下降,尽管在CD患者中市场渗透强劲。
  • CD患者中英夫利昔单抗使用不当和UC患者中使用不足可能 largely 解释研究发现。

研究设计与样本

  • 基于人群的间断时间序列研究,使用加拿大安大略省1995-2012年成人CD和UC患者卫生行政数据。
  • 采用分段回归分析评估英夫利昔单抗上市对IBD相关住院、肠切除和公共支付药物成本的影响,CD患者观察10年,UC患者观察5年,允许1年过渡期。

主要发现

  • 与无英夫利昔单抗的预期趋势相比,英夫利昔单抗上市未显著降低CD相关住院率(最后观察季度OR 1.06,95% CI 0.811至1.39)或肠切除率(OR 1.10,95% CI 0.810至1.50)。
  • 英夫利昔单抗上市未显著降低UC相关住院率(OR 1.22,95% CI 1.07至1.39)或结肠切除率(OR 0.933,95% CI 0.54至1.61)。
  • 在英夫利昔单抗使用者中,UC患者住院率在英夫利昔单抗上市后显著下降(OR 0.515,95% CI 0.342至0.777)。
  • CD患者公共支付药物成本较预期趋势上升约三倍(OR 2.98,95% CI 2.29至3.86),UC患者无显著变化(OR 1.06,95% CI 0.955至1.18)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To better understand the real-world impact of biologic therapy in persons with Crohn's disease (CD) and ulcerative colitis (UC), we evaluated the effect of marketplace introduction of infliximab on the population rates of hospitalisations and surgeries and public payer drug costs. DESIGN: We used health administrative data to study adult persons with CD and UC living in Ontario, Canada between 1995 and 2012. We used an interrupted time series design with segmented regression analysis to evaluate the impact of infliximab introduction on the rates of IBD-related hospitalisations, intestinal resections and public payer drug costs over 10 years among patients with CD and 5 years among patients with UC, allowing for a 1-year transition. RESULTS: Relative to what would have been expected in the absence of infliximab, marketplace introduction of infliximab did not produce significant declines in the rates of CD-related hospitalisations (OR at the last observation quarter 1.06, 95% CI 0.811 to 1.39) or intestinal resections (OR 1.10, 95% CI 0.810 to 1.50), or in the rates of UC-related hospitalisations (OR 1.22, 95% CI 1.07 to 1.39) or colectomies (OR 0.933, 95% CI 0.54 to 1.61). The findings were similar among infliximab users, except that hospitalisation rates declined substantially among UC patients following marketplace introduction of infliximab (OR 0.515, 95% CI 0.342 to 0.777). There was a threefold rise over expected trends in public payer drug cost among patients with CD following infliximab introduction (OR 2.98,95% CI 2.29 to 3.86), suggesting robust market penetration in this group, but no significant change among patients with UC (OR 1.06, 95% CI 0.955 to 1.18). CONCLUSIONS: Marketplace introduction of infliximab has not yielded anticipated reductions in the population rates of IBD-related hospitalisations or intestinal resections, despite robust market penetration among patients with CD. Misguided use of infliximab in CD patients and underuse of infliximab in UC patients may largely explain our study findings.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Murthy SK, Begum J, Benchimol EI, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2019. PMID: 31196874. doi:10.1136/gutjnl-2019-318440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。